Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 12;21(2):1679-1687.
doi: 10.1007/s40200-022-01120-1. eCollection 2022 Dec.

Stem cell therapy for type 1 diabetes: a scientometric assessment of global research during the twenty-first century

Devi Dayal  1 , Brij Mohan Gupta  2 , Ghouse Modin Mamdapur  3 , Latika Rohilla  4 , Pamali Mahasweta Nanda  4
Affiliations

Stem cell therapy for type 1 diabetes: a scientometric assessment of global research during the twenty-first century

Devi Dayal et al. J Diabetes Metab Disord. .

Abstract

Purpose: We aimed to provide a scientometric assessment of global research in stem cell therapy (SCT) for type 1 diabetes (T1D) during 1999-2020.

Methods: The published data on SCT in T1D were retrieved from Elsevier's Scopus database and analyzed using select bibliometric tools. We used VOSviewer software and the Biblioshiny app to construct and visualize bibliometric networks.

Results: The global yield totaled 1806 publications in the 22-year study period, registering a 17.7% annual growth peaking at 196.9% in the last 11 years. The average citations per publication (CPP) decreased from 62.0 during 1999-2009 to 24.3 during 2010-2020. The funded publications were 727 (40.2%). Randomized controlled trials (RCTs) were only 2.4% (45). Amongst 70 participating countries, the USA led with a 38.6% share. Of the 388 global organizations, Harvard Medical School, USA, San Raffaele Scientific Institute, Italy, and the University of Florida, USA were the topmost contributors. Florina, Couri, and Trucco were the top productive authors, whereas Melton, Abdi, and Simoes were the most impactful. Only 129 (3.1%) publications were highly-cited; their total and average CPP were 31,228 and 214.0 (range 101-1841), respectively.

Conclusions: The quantity of research in SCT for T1D has increased during the last two decades while the quality has dipped. The research landscape is dominated by high-income North-American and Western-European countries. There is a need for conducting large-scale RCTs and promoting research collaborations between high- and low-income countries for long-term sustainability and global impact.

Keywords: Bibliometrics; Global publications; Scientometrics; Stem cell therapy; Treatment; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Competing interestsNone.

Figures

Fig. 1
Fig. 1
Flow chart of data collection and analysis
Fig. 2
Fig. 2
WorldCloud sketch of the top 50 keywords. The significance of every tag is displayed with text dimension or shading with the bigger term implying more significance
Fig. 3
Fig. 3
Collaboration network of the top 12 countries generated using the Biblioshiny app. The countries with the same colour belong to a single cluster, the thickness of the linking lines and the distance between countries represents the degree of collaborative relationships. The diameter and font size of the node represents the value of a country in research collaboration
Fig. 4
Fig. 4
Collaboration network of the prime organizations in research on stem cell therapy for type 1 diabetes. The box size and text dimension of each hub are relative to the organization’s research yield
Fig. 5
Fig. 5
The author collaboration network on stem cell therapy for type 1 diabetes. The top 20 authors are grouped into eight clusters; cluster 1 consists of 6 authors, clusters 2 and 3 of 3 authors each, clusters 4, 5 and 6 of 2 authors each, and clusters 7 and 8 of one author each
Fig. 6
Fig. 6
Network visualization of the citation counts of the 129 highly-cited publications in stem cell therapy for type 1 diabetes
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Patterson CC, Karuranga S, Salpea P, Saeedi P, Dahlquist G, Soltesz G, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents Results from the International Diabetes Federation Diabetes Atlas 9th edition. Diabetes Res Clin Pract. 2019;157:107842. doi: 10.1016/j.diabres.2019.107842. - DOI - PubMed
    1. Gupta BM, Dayal D. Pediatric Type 1 Diabetes Research in the 21st Century: A Scientometric Review. Pediatr Endocrinol Diabetes Metab. 2020;26:132–139. doi: 10.5114/pedm.2020.98165. - DOI - PubMed
    1. Drucker DJ. Transforming type 1 diabetes: the next wave of innovation. Diabetologia. 2021;64:1059–1065. doi: 10.1007/s00125-021-05396-5. - DOI - PubMed
    1. Paul M, Dayal D, Bhansali A, Dhaliwal L, Sachdeva N. In vitro assessment of cord blood-derived proinsulin-specific regulatory T cells for cellular therapy in type 1 diabetes. Cytotherapy. 2018;20:1355–1370. doi: 10.1016/j.jcyt.2018.09.004. - DOI - PubMed
    1. Boscari F, Avogaro A. Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Rev Endocr Metab Disord. 2021;22:217–240. doi: 10.1007/s11154-021-09635-3. - DOI - PMC - PubMed

LinkOut - more resources